Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

Hello, and welcome, everyone, to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky, and I'll be your operator today. (Operator Instructions) I will now hand over to your host, Head of ...

Glioblastoma Multiforme Treatment Market size is expected to reach USD 4.7 Billion by 2033 from USD 2.2 Billion in 2023, at a CAGR of 8.1%. Lawrence John Prudour +91 91308 55334 ...